Exploring the outcome of multiple sclerosis among Saudi adult patients

References

1. ↵
   1. Goldman L

   , ed (2012) Cecil Medicine (Elsevier, Philadelphia (PA)), 24th ed.
2. ↵
   1. Thompson A

   (2013) Atlas of MS 2013 Multiple Sclerosis International Federation (WHO, London), 60.
3. ↵
   1. Bohlega S,
   2. Inshasi J,
   3. Al Tahan AR,
   4. Madani AB,
   5. Qahtani H,
   6. Rieckmann P

   (2013) Multiple sclerosis in the Arabian Gulf countries:a consensus statement. J Neurol 260, 2959–2963.
4. ↵
   1. Al Wutayd O,
   2. Mohamed AG,
   3. Saeedi J,
   4. Al Otaibi H,
   5. Al Jumah M

   (2018) Environmental exposures and the risk of multiple sclerosis in Saudi Arabia. BMC Neurol 18, 86.
5. ↵
   1. Salehpoor G,
   2. Kafi S,
   3. Rezaei S,
   4. Hosseininezhad M,
   5. Salehi I

   (2012) The relation between fatigue severity with psychological symptoms and quality of life in patients Multiple Sclerosis. Zahedan J Res Med Sci 14, 80–86.
6. ↵
   1. Raffel J,
   2. Wallace A,
   3. Gveric D,
   4. Reynolds R,
   5. Friede T,
   6. Nicholas R

   (2017) Patient-reported outcomes and survival in multiple sclerosis:A 10-year retrospective cohort study using the Multiple Sclerosis Impact Scale-29. PLoS Med 14, e1002346.
7. ↵
   1. Huda S,
   2. Cavey A,
   3. Izat A,
   4. Mattison P,
   5. Boggild M,
   6. Palace J

   (2016) Nurse led telephone assessment of expanded disability status scale assessment in MS patients at high levels of disability. J Neurol Sci 362, 66–68.
8. ↵
   1. Wilson JT,
   2. Hareendran A,
   3. Hendry A,
   4. Potter J,
   5. Bone I,
   6. Muir KW

   (2005) Reliability of the modified Rankin Scale across multiple raters:benefits of a structured interview. Stroke 36, 777–781.
9. ↵
   1. Hobart J,
   2. Lamping D,
   3. Fitzpatrick R,
   4. Riazi A,
   5. Thompson A

   (2001) The Multiple Sclerosis Impact Scale (MSIS-29):a new patient-based outcome measure. Brain 124, 962–973.
10. ↵
    1. Collin C,
    2. Wade DT,
    3. Davies S,
    4. Horne V

    (1988) The Barthel ADL Index:a reliability study. Int Disabil Stud 10, 61–63.
11. ↵
    1. Sulter G,
    2. Steen C,
    3. De Keyser J

    (1999) Use of the Barthel index and modified Rankin scale in acute stroke trials. Stroke 30, 1538–1541.
12. ↵
    1. Kerbrat A,
    2. Hamonic S,
    3. Leray E,
    4. Tron I,
    5. Edan G,
    6. Yaouanq J

    (2015) Ten-year prognosis in multiple sclerosis:a better outcome in relapsing-remitting patients but not in primary progressive patients. Eur J Neurol 22, 507–e535.
13. ↵
    1. Scalfari A,
    2. Neuhaus A,
    3. Degenhardt A,
    4. Rice GP,
    5. Muraro PA,
    6. Daumer M,
    7. et al.

    (2010) The natural history of multiple sclerosis:a geographically based study 10:relapses and long-term disability. Brain 133, 1914–1929.
14. ↵
    1. Abulaban A,
    2. Altowairqi A,
    3. Altowairqi H,
    4. Almutairi A,
    5. Altalhi S,
    6. Alotaibi F,
    7. et al.

    (2017) Quality of life in multiple sclerosis patients in Saudi Arabia and some Arab countries. American Academy of Neurology 88, 3.330.
15. ↵
    1. Nicholl L,
    2. Hobart J,
    3. Dunwoody L,
    4. Cramp F,
    5. Lowe-Strong A

    (2004) Measuring disability in multiple sclerosis:is the Community Dependency Index an improvement on the Barthel Index? Mult Scler 10, 447–450.
16. ↵
    1. Conwit R,
    2. Cofield S,
    3. Cutter G,
    4. Wolinsky J,
    5. Lublin F

    (2018) The Modified Rankin Score Compared to EDSS and MRI Measures Using CombiRx Baseline Assessments [Internet]. CombiRx, Available from: http://citeseerx.ist.psu.edu/viewdoc/download;jsessionid=D728CC187D97F8ED78582DCC2996F75E?doi=10.1.1.606.9153&rep=rep1&type=pdf. Accessed 28 Mary2018.
17. ↵
    1. Rabadi MH,
    2. Vincent AS

    (2013) Comparison of the Kurtkze expanded disability status scale and the functional independence measure:measures of multiple sclerosis-related disability. Disabil Rehabil 35, 1877–1884.
18. ↵
    1. Marrie RA,
    2. Horwitz R,
    3. Cutter G,
    4. Tyry T,
    5. Campagnolo D,
    6. Vollmer T

    (2009) Comorbidity delays diagnosis and increases disability at diagnosis in MS. Neurology 72, 117–124.
19. ↵
    1. Shirani A,
    2. Zhao Y,
    3. Petkau J,
    4. Gustafson P,
    5. Karim ME,
    6. Evans C,
    7. et al.

    Multiple sclerosis in older adults:the clinical profile and impact of interferon Beta treatment. Biomed Res Int 2015 2015, 451912.
20. ↵
    1. Alhazzani A,
    2. Alqahtani M,
    3. Alahmari M,
    4. Asiri M,
    5. Alamri N,
    6. Sarhan L,
    7. et al.

    (2017) Quality of life assessment among multiple sclerosis patients, cross sectional study, Saudi Arabia. Journal of the Neurological Sciences 381, 237.